Beta
36646

Evaluation of tumor marker (PIVAK-II) in patients with positive HCV infection with and without cirrhosis complicated and uncomplicated with hepatocellular carcinoma

Thesis

Last updated: 06 Feb 2023

Subjects

-

Tags

Internal Medicine

Advisors

Amin, Ebrahim G. , El-Anssari, Mirvat , El-Gendi, Hala E.

Authors

El-Numairi, Emad Saleh Hammouda

Accessioned

2017-03-30 06:19:27

Available

2017-03-30 06:19:27

type

M.D. Thesis

Abstract

High incidence of hepatocellular carcinoma (HCC) is linked to increased chronic HCV infection. Chronic hepatitis (CH), liver cirrhosis (LC), and HCC are now accepted sequelae , especially in chronic Hepatitis C virus infection. In this study the tumor marker, protein induced by vitamin k absence or antagonist II (PIVKA-II) and Alfa fetoprotein (AFP) was estimated in 50 patients with HCV positive (20 patients with HCC, 15 patients with LC, 15 patients hepatitis C virus positive only) and 10 healthy subjects. PIVKA-II level was significantly increased in HCC group compared to other groups and was correlated to tumor size and portal vein thrombosis with a higher sensitivity and specificity than AFP

Issued

1 Jan 2005

Details

Type

Thesis

Created At

28 Jan 2023